AMAG PHARMACEUTICALS, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $75.8M | $117.4M | $495.8M | $432.5M | $89.5M | $20.8M |
| Operating income | −$445.5M | −$47.0M | −$303.8M | $85.1M | $111.2M | −$3.8M |
| Net income | −$122.1M | −$54.2M | −$199.2M | −$2.5M | $32.8M | — |
| Total assets | $791.2M | $1.18B | $1.90B | $2.48B | $2.49B | $1.39B |
| Total liabilities | $505.1M | $428.8M | $1.11B | $1.54B | $1.56B | $929.0M |
| Equity | $286.1M | $746.7M | $790.2M | $934.4M | $932.3M | $460.0M |
| EPS (diluted) | — | $-1.59 | $-1.06 | $-0.07 | $0.93 | $5.45 |
| Shares out. | 34.7M | 34.1M | 34.3M | 34.7M | 25.6M | 21.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −587.7%
- Net margin
- −161.1%
- Return on equity
- −42.7%
- Return on assets
- −15.4%
- Return on capital (ROCE)
- −76.4%
- Liabilities / assets
- 63.8%
- Debt / equity
- 1.77×
- Book value / share
- $8.24
- Revenue growth (YoY)
- −35.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -6.45distress
- Accruals / assets
- 0.5%clean
- Piotroski F-Score
- 0/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 11, 2020
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2026-07A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
- Phase 3Recruitingreadout ~2026-08-31A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- New financial obligationNov 17, 2020
- Entered a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsNov 17, 2020
- Regulation FD disclosure · Other material eventOct 6, 2020
- Entered a material agreement · Regulation FD disclosureOct 1, 2020
- Other material eventAug 17, 2020
- Results of operations · Director / officer changeAug 6, 2020
- Entered a material agreement · Terminated a material agreement · Regulation FD disclosureJul 27, 2020
- Entered a material agreementJul 23, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 16, 2021
- SC 13G/APRIMARY DOCUMENTFeb 16, 2021
- SC 13G/AFeb 10, 2021
- 15-12BFORM 15-12BNov 27, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
- S-8 POSAMENDMENT NO. 1Nov 24, 2020
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.